Santen SAS
Clinical trials sponsored by Santen SAS, explained in plain language.
A subsidiary of Santen Pharmaceutical, focusing on ophthalmology products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Tiny tube could tame glaucoma without daily drops Results expected Sep 2027 (estimated)
-
Tiny tube could tame glaucoma without daily drops
Disease control Recruiting nowThis study tests a small implant called the PRESERFLO™ MicroShunt XI in people with primary open-angle glaucoma whose eye pressure remains high despite maximum medication. The implant is placed under the eye's surface to drain fluid and lower pressure. Researchers will check if i…
Sponsor: Santen SAS • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Eye drops could replace surgery for droopy eyelids
Symptom relief Recruiting nowThis Phase 3 trial tests whether oxymetazoline eye drops can safely lift droopy eyelids (acquired blepharoptosis) in 234 adults. Participants use the drops twice daily for 14 days. The main goal is to measure how much the eyelid lifts, and patients will also report if they feel i…
Phase 3 • Sponsor: Santen SAS • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC